|
ORF cDNA clones
|
CRISPR / TALEN
|
Lentivirus
|
AAV
|
TALE-TF
|
ORF knockin clones
|
|
Antibody
|
Proteins
|
miRNA target clones
|
qPCR primers
|
shRNA clones
|
miRNA products
|
Promoter clones
|
Validated All-in-One™ qPCR Primer for FGFR4(NM_213647.3) Search again
Powered by BiozBy default, qPCR primer pairs are designed to measure the expression level of the splice variant (accession number) you selected for this gene WITHOUT consideration of other possible variants of this gene. If this gene has multiple variants, and you would like to measure the expression levels of one particular variant, multiple variants, or all variants, please contact us for a custom service project at inquiry@genecopoeia.com.
Summary
The protein encoded by this gene is a member of the fibroblast growth factor receptor family, where amino acid sequence is highly conserved between members and throughout evolution. FGFR family members differ from one another in their ligand affinities and tissue distribution. A full-length representative protein would consist of an extracellular region, composed of three immunoglobulin-like domains, a single hydrophobic membrane-spanning segment and a cytoplasmic tyrosine kinase domain. The extracellular portion of the protein interacts with fibroblast growth factors, setting in motion a cascade of downstream signals, ultimately influencing mitogenesis and differentiation. The genomic organization of this gene, compared to members 1-3, encompasses 18 exons rather than 19 or 20. Although alternative splicing has been observed, there is no evidence that the C-terminal half of the IgIII domain of this protein varies between three alternate forms, as indicated for members 1-3. This particular family member preferentially binds acidic fibroblast growth factor and, although its specific function is unknown, it is overexpressed in gynecological tumor samples, suggesting a role in breast and ovarian tumorigenesis. [provided by RefSeq].
Gene References into function
- distribution in normal endocrine cells and related tumors of the gastroenteropancreatic system; immunoreactive in rectal L cells and in pancreatic B, PP, and A cells
- Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele.
- FGFR4 expression in astrocytomas correlates with median survival times of the patients.
- findings suggest a novel transcriptional contribution of Ikaros with Ets and Sp1 in regulation of FGFR4 in the pituitary
- Differences in spatial patterns of FGFR expression in normal skin may generate functional diversity in response to FGFs, and in wounded skin FGFs may function in wound healing via induced FGFRs.
- recognition of cryptic promoter in intron 4 by pituitary tumor AP-2alpha
- Fibroblast growth factor receptor 4 (FGFR4) is associated with a poor prognosis in breast cancer patients.
- G388R mutation of the FGFR4 gene is not relevant for breast cancer prognosis
- Role for pituitary tumor-derived FGFR4 in pituitary tumorigenesis in a majority of human pituitary adenomas. Detection of FGFR4 cytoplasmic staining may provide ancillary diagnostic tool in diagnosis of pituitary adenoma, particularly in equivocal cases.
- a tumor-derived FGFR4 isoform provides a novel mechanism beyond ligand independence that explains the pathobiology of proliferative and infiltrative but nonmetastatic neoplasms.
- the FGFR-4 Arg388 allele is associated with both an increased incidence and clinical aggressiveness of prostate cancer
- FGFR-4 may have a role in human thyroid cancer cell progression
- Transgenic hepatocyte FGFR4 may contribute to the repression of bile acid synthesis through c-Jun N-terminal kinase (JNK) signaling but is not required for activation of JNK signaling by bile acids.
- FGFR4 polymorphism may not be relevant in predicting nodal involvement of breast cancer or colon cancer patients.
- Data indicate that after endocytosis, fibroblast growth factor receptor (FGFR)4 and its bound ligand, FGF1, are sorted mainly to the recycling compartment, whereas FGFR1-3 with ligand are sorted mainly to degradation in the lysosomes.
- We conclude that FGFR4 germline polymorphism G388 suppresses cell motility of invasive breast cancer cells by altering signalling pathways and the expression of genes that are required for metastasis.
- For the first time in humans, the expression of basic fibroblast growth factor (bFGF) and its receptors FGFR-2, FGFR-3, and FGFR-4 has been documented in ovaries of second- and third-trimester fetuses.
- little evidence to support the tenet that the FGFR4 Gly388Arg polymorphism is a clinically useful marker for lung cancer prognosis
- Fibroblast growth factor FGF19 and its cognate receptor FGFR4 are coexpressed in primary human liver, lung, and colon tumors and xenograft tissues and in a subset of human colon cancer cell lines, where their interactions are important for tumor growth.
- FGFR4 plays essential roles in systemic lipid and glucose homeostasis, as seen in knockout and transgenic mice.
- High FGFR4 mRNA levels were associated with failure on tamoxifen therapy in patients with recurrent breast cancer
- The FGFR4 Gly388Arg polymorphism had consistent associations with survival outcomes in head and neck neoplasms.
- FGF19/FGFR4 cross-talk with beta-catenin and that pathway intervention reduces tumor growth.
- The increased receptor stability and sustained FGFR-4 signaling occur in most human prostate cancers due to either the presence of a common genetic polymorphism or the expression of a protein that stabilizes FGFR-4.
- FGFR4 Arg allele of the Gly388Arg polymorphism and the G allele of the rs2011077 polymorphism have a significant impact on the development of prostate cancer and benign prostatic hyperplasia
- FGFR4 polymorphism is a prognostic marker for advanced NSCLC in Japanese patients.
- FGFR4 contributes significantly to hepatocellular carcinoma progression by modulating alpha-fetoprotein secretion, proliferation and anti-apoptosis.